Does TRICARE Cover Trulicity?

How TRICARE Classifies Trulicity on Its Formulary

TRICARE pharmacy benefits are administered by Express Scripts under the Department of Defense (DoD) Pharmacy Operations Directorate. Trulicity (dulaglutide) appears on the TRICARE formulary as a non-preferred branded agent within the GLP-1 receptor agonist class 1. This classification means it is covered but carries a higher copay than preferred alternatives and requires prior authorization before dispensing.

Formulary Tier Breakdown by Pharmacy Channel

The DoD Uniform Formulary places drugs into tiers that determine cost-sharing. At military treatment facility (MTF) pharmacies, Trulicity carries a $0 copay when stocked. Retail network pharmacies charge Tier 3 copays, while the Express Scripts mail-order program offers a lower cost for 90-day fills 2. TRICARE For Life beneficiaries who also have Medicare Part D may see different tier placement depending on their Part D plan's own formulary.

How Non-Preferred Status Affects Access

Non-preferred status does not mean denial. It signals that TRICARE wants prescribers to try preferred agents first. Within the GLP-1 class, semaglutide (Ozempic) has periodically held preferred status on the DoD formulary, though formulary rankings shift during contract cycles 3. Prescribers can still obtain Trulicity approval by documenting clinical need through the prior-authorization pathway.

Prior Authorization Criteria for Trulicity on TRICARE

TRICARE requires prior authorization (PA) for all non-preferred GLP-1 receptor agonists. The PA process is administered by Express Scripts, which evaluates requests against clinical criteria set by the DoD Pharmacy and Therapeutics (P&T) Committee 4.

What the PA Application Must Include

A complete PA submission typically requires three elements: a confirmed diagnosis of type 2 diabetes (ICD-10 E11.x), documentation that the patient has tried and failed (or has a contraindication to) at least one preferred formulary agent, and a recent HbA1c value showing inadequate glycemic control. The American Diabetes Association (ADA) Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin in patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk 5. Including this guideline reference in the PA request strengthens the clinical justification.

Approval Turnaround and Duration

Standard PA review takes 5 to 10 business days through Express Scripts. Urgent requests may receive a 72-hour turnaround. Approvals are typically granted for 12 months. The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite cardiovascular endpoint (nonfatal MI, nonfatal stroke, or CV death) by 12% over a median 5.4 years versus placebo (HR 0.88; 95% CI 0.79 to 0.99) 6. Citing REWIND in the PA narrative helps justify the choice of dulaglutide specifically over other agents.

Common Reasons for PA Denial

Denials most often occur when the prescriber omits step-therapy documentation, submits an incomplete form, or requests Trulicity for weight management rather than diabetes. TRICARE does not cover dulaglutide for obesity as a standalone indication because the drug lacks an FDA weight-loss approval 7.

Step Therapy Requirements Before Trulicity

TRICARE's step-therapy protocol requires beneficiaries to demonstrate a trial of metformin (or document a medical reason for intolerance) before the plan authorizes a GLP-1 receptor agonist 8. This aligns with ADA guidelines that position metformin as first-line pharmacotherapy for type 2 diabetes.

What Counts as a Completed Step

A minimum 90-day trial of metformin at therapeutic doses (1,500 to 2,000 mg/day) with a follow-up HbA1c showing persistent hyperglycemia (generally HbA1c ≥7.0%) satisfies the step requirement. Documented intolerance (severe GI side effects, lactic acidosis risk, eGFR <30 mL/min/1.73 m²) qualifies as a clinical bypass 9. Patients with an eGFR below 30 have a contraindication to metformin per FDA labeling, so step therapy is waived.

Bypassing Step Therapy

In some cases prescribers can request an exception to skip the metformin step. Evidence of ASCVD, heart failure, or chronic kidney disease (CKD) stage 3+ may qualify. The 2024 ADA/EASD consensus report recommends GLP-1 receptor agonists as first-line alongside metformin in high-risk patients 10. A letter of medical necessity citing this recommendation, along with supporting labs (troponin, BNP, eGFR), can override step therapy.

Out-of-Pocket Costs for Trulicity Under TRICARE

Cost-sharing varies significantly by TRICARE plan type and pharmacy channel.

TRICARE Prime Copays

Active-duty service members pay $0 for all prescriptions at MTF pharmacies. TRICARE Prime dependents pay $14 for a 30-day generic, $36 for a 30-day non-preferred brand at retail, and $29 for a 90-day non-preferred brand through mail order 11. Trulicity falls into the non-preferred brand tier at most retail outlets.

TRICARE Select and For Life

TRICARE Select enrollees face a $34 retail copay for preferred brands and up to $72 for non-preferred brands per 30-day fill after meeting the annual deductible ($176 individual / $352 family for retirees in 2025). TRICARE For Life, which wraps around Medicare, typically covers Trulicity through Part D; beneficiaries should check their Part D plan's formulary rather than relying solely on the TRICARE pharmacy benefit 12.

Comparing Costs: Retail vs. Mail Order vs. MTF

Mail order through Express Scripts is almost always the cheapest option for maintenance medications. A 90-day Trulicity supply via mail order costs roughly $29 for TRICARE Prime dependents, versus $108 ($36 × 3) for three monthly retail fills. The list price without any insurance is approximately $931 per month 13.

How to Appeal a TRICARE Denial of Trulicity

If TRICARE denies a Trulicity PA request, beneficiaries have the right to appeal through a structured process.

First-Level Appeal: Reconsideration

The first step is filing a reconsideration request with the TRICARE regional contractor (Humana Military for the East Region or Health Net Federal Services for the West Region). The appeal must include a letter from the prescribing physician explaining why Trulicity is medically necessary, any new clinical evidence (updated labs, prior medication failures), and a copy of the denial letter 14. Submission deadline is 90 days from the initial denial notice.

Second-Level Appeal: Formal Review

If reconsideration fails, beneficiaries can escalate to a formal appeal with the TRICARE ECHO contractor. This level of review involves an independent medical review by a physician who was not part of the original decision. Second-level appeals have a higher overturn rate when the submission includes published clinical evidence supporting dulaglutide use 15. The AWARD-7 trial (N=577) showed dulaglutide 1.5 mg preserved eGFR in patients with moderate-to-severe CKD and type 2 diabetes compared to insulin glargine (between-group difference +3.0 mL/min/1.73 m² at 52 weeks) 16. For patients with CKD, citing AWARD-7 adds weight to the appeal.

Timeline and What to Expect

First-level reconsiderations typically receive a decision within 30 days. Formal second-level appeals take 45 to 60 days. During the appeal process, beneficiaries can request a temporary supply (up to 30 days) through the TRICARE point-of-service option, though this carries higher out-of-pocket costs 17.

Trulicity for Weight Loss: Why TRICARE Does Not Cover It

Dulaglutide is FDA-approved only for type 2 diabetes. It does not carry an FDA-approved indication for chronic weight management 18. TRICARE explicitly excludes off-label weight-loss use of GLP-1 receptor agonists that lack an obesity indication.

GLP-1 Agents TRICARE Does Cover for Weight Loss

TRICARE has covered Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) for obesity with PA since 2024, following a DoD policy update. Both require documented BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity 19. The STEP 1 trial (N=1,961) demonstrated 14.9% mean body weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo 20.

Off-Label Use and Documentation Risks

Prescribers who submit a PA for Trulicity citing weight management as the primary indication will receive an automatic denial. If a patient with type 2 diabetes also needs weight loss support, the PA should list glycemic control as the primary indication while noting BMI reduction as a secondary clinical benefit 21. Dr. Robert Gabbay, Chief Scientific and Medical Officer of the ADA, has stated: "GLP-1 receptor agonists offer glycemic and cardiovascular benefits that go well beyond A1c reduction" 22.

Clinical Evidence Supporting Trulicity Coverage Decisions

TRICARE formulary decisions are informed by the DoD P&T Committee, which reviews key trials and real-world evidence.

Cardiovascular Outcomes: The REWIND Trial

REWIND enrolled 9,901 patients with type 2 diabetes (31.5% with prior cardiovascular events) across 24 countries. Over a median 5.4-year follow-up, dulaglutide 1.5 mg weekly reduced the primary composite MACE endpoint by 12% (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) 23. REWIND was the longest-duration cardiovascular outcome trial for any GLP-1 receptor agonist at the time of publication.

Renal Protection: AWARD-7

The AWARD-7 trial demonstrated that dulaglutide slowed the decline of kidney function compared to insulin glargine in patients with CKD stage 3 to 4 and type 2 diabetes. At 52 weeks, eGFR declined by 0.7 mL/min/1.73 m² in the dulaglutide 1.5 mg group versus 3.3 mL/min/1.73 m² in the insulin glargine group 24. These data are particularly relevant for military retirees, who are older on average and carry higher CKD prevalence.

Glycemic Efficacy: AWARD Trial Program

Across the AWARD program, dulaglutide 1.5 mg consistently reduced HbA1c by 1.1 to 1.6 percentage points from baseline 25. The ADA notes that GLP-1 receptor agonists provide "high" glucose-lowering efficacy with low hypoglycemia risk 26.

Tips for Military Beneficiaries Seeking Trulicity Coverage

A few practical steps can increase the likelihood of approval and reduce cost.

Use Mail Order Whenever Possible

Express Scripts mail-order pharmacy consistently provides the lowest copays for TRICARE beneficiaries. Set up automatic refills to avoid gaps in therapy. Dulaglutide requires cold-chain shipping; Express Scripts uses insulated packaging with temperature monitors for injectable medications 27.

Ask Your Prescriber to Pre-Load the PA

Before writing the first prescription, ask your provider to submit the PA with all required documentation (metformin trial records, recent HbA1c, any contraindication notes). A pre-loaded PA prevents the common scenario where a beneficiary arrives at the pharmacy only to learn the claim was rejected.

Know Your Regional Contractor

TRICARE East (Humana Military) and TRICARE West (Health Net Federal Services) handle PA and appeals separately. The Endocrine Society's 2022 clinical practice guideline recommends GLP-1 receptor agonists for type 2 diabetes patients with ASCVD or high cardiovascular risk regardless of HbA1c level 28. Citing this guideline in PA requests aligns clinical reasoning with national standards.

Manufacturer Savings Cards Do Not Apply

Eli Lilly offers a Trulicity savings card for commercially insured patients, but federal law prohibits applying manufacturer coupons to TRICARE, Medicare, Medicaid, and other government-funded insurance programs 29. TRICARE beneficiaries cannot use these cards at any pharmacy.

The lowest-cost route for Trulicity on TRICARE remains a 90-day mail-order fill through Express Scripts with an active prior authorization, yielding a copay of approximately $29 per quarter for Prime dependents.